Clinical Trials Logo

Leukemia, Myelocytic, Acute clinical trials

View clinical trials related to Leukemia, Myelocytic, Acute.

Filter by:

NCT ID: NCT00136084 Completed - Clinical trials for Leukemia, Myelocytic, Acute

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

Start date: August 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.

NCT ID: NCT00126321 Recruiting - Clinical trials for Leukemia, Myelocytic, Acute

Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)

Start date: November 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and the efficacy of cladribine, high-dose cytarabine and idarubicin in the treatment of patients with relapsed acute myeloid leukemia.

NCT ID: NCT00067002 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Randomized Double Cord Blood Transplant Study

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if combining cord blood units to make the cells "take" faster in recipients will help to improve the results of cord blood transplants.

NCT ID: NCT00048100 Terminated - Clinical trials for Leukemia, Myelocytic, Acute

Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes

Start date: February 2001
Phase: Phase 1
Study type: Interventional

Objectives: 1. Determine the toxicity of infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL) in relapsed patients after allo-stem cell transplants. 2. Quantitate the alloreactivity of DC/ADL and circulating immune effector cells in patients after infusion. 3. Assess efficacy of acute myelogenous leukemia (AML) or Chronic Myelogenous Leukemia in Blastic Crisis (CML-BC) derived dendritic cells and activated lymphocytes in promoting and sustaining remission in patients with relapse after allo-BMT or stem cell transplant.

NCT ID: NCT00044486 Completed - Clinical trials for Myelodysplastic Syndromes

Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)

Start date: July 2002
Phase: Phase 3
Study type: Interventional

This trial is in high risk patients to determine the safety and efficacy of posaconazole vs. fluconazole in the prophylaxis against development of invasive fungal infections. Profound, prolonged neutropenia (Absolute neutrophil count<500 cells/cubic mm for at least 7 days) due to induction chemotherapy for acute myelogenous leukemia, or myelodysplastic syndrome. Treatment Duration: maximum of 12 weeks Follow-Up 2 months. Endpoints: incidence of proven or probable IFI according to EORTC/MSG criteria within the neutropenic episode and within 100 days of randomization as determined by external expert review.

NCT ID: NCT00000589 Completed - Clinical trials for Hematologic Diseases

Trial to Reduce Alloimmunization to Platelets (TRAP)

Start date: August 1989
Phase: Phase 3
Study type: Interventional

To determine the best, clinically useful procedure to prevent or minimize platelet alloimmunization as a cause of refractoriness to platelet transfusion in patients undergoing marrow ablative chemotherapy for acute myelogenous leukemia.